This looks like great news for the company, albeit preliminary as there are still a few cohorts in the Phase 1b to go (next data due early in January).
1. I'm curious how the mean 5-day log drop of 3.94 log10 compares to telaprevir and the other PIs. There is no way to do an apples-to-apples comparison I assume as most of the other HCV PIs measured their initial PoC potency data at 3 days I believe.
2. Perhaps more important than the potency data (as we have discussed before on here), the initial safety data in HCV-infected patients looks clean.
3. A key question for me centers around the fact that this initial data is from BID dosing. The goal is for ACH-1625 to be dosed QD, as that has been perceived as a potential differentiating advantage for ACH-1625. The BID dose was 600mg so I'm assuming that at least one of the remaining cohorts is testing ACH-1625 at a higher potency and at QD dosing.
4. It is noted that viral load remained suppressed for at least 7 days after dosing was completed. Isn't it normal for viral loads to quickly rebound in these studies? If so, I presume that this is potentially a good differentiating characteristic for ACH-1625.
Market Data 
Markets 
AI
